Amgen Inc.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It's Moving
Amgen rides high on low-volatility appeal and obesity drug buzz amid biotech stability.
Amgen stands out as one of the best low-volatility investments for December 2025, drawing investor focus as biotech peers face turbulence. Goldman Sachs held its Buy rating ahead of key Phase 2 data for obesity hopeful MariTide, signaling potential breakthroughs in a high-stakes market.
- Goldman Sachs reaffirmed $400 price target and Buy rating on Nov 25, citing upcoming Part 2 maintenance data from MariTide's Phase 2 trial that could validate its edge in obesity treatments.[1]
- Amgen named among top low-volatility stocks for December, offering stability in a volatile biotech sector amid broader market pauses.[1]
- Recent Q4 dividend announcement underscores commitment to shareholder returns, with payment set for Dec 12 amid steady stock trading around $317-$320.[7]
Amgen rides high on low-volatility appeal and obesity drug buzz amid biotech stability.
Amgen stands out as one of the best low-volatility investments for December 2025, drawing investor focus as biotech peers face turbulence. Goldman Sachs held its Buy rating ahead of key Phase 2 data for obesity hopeful MariTide, signaling potential breakthroughs in a high-stakes market.
- Goldman Sachs reaffirmed $400 price target and Buy rating on Nov 25, citing upcoming Part 2 maintenance data from MariTide's Phase 2 trial that could validate its edge in obesity treatments.[1]
- Amgen named among top low-volatility stocks for December, offering stability in a volatile biotech sector amid broader market pauses.[1]
- Recent Q4 dividend announcement underscores commitment to shareholder returns, with payment set for Dec 12 amid steady stock trading around $317-$320.[7]
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Amgen's stock as it has potential for growth based on its target price.
Financial Health
Amgen is showing strong revenue, profits, and cash flow, indicating solid financial stability.
Dividend
Amgen's dividend yield of 2.89% indicates a decent return for dividend-seeking investors. If you invested $1000 you would be paid $28.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AMGN
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
